Hilton Worldwide has been granted a patent for a method of treating keloids using hypoxia-inducible factor-1 (HIF-1) inhibiting compounds. The method involves administering a therapeutically effective amount of the compound to induce cell death in keloids. GlobalData’s report on Hilton Worldwide gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Hilton Worldwide Holdings Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hilton Worldwide, Location-based parallel gaming was a key innovation area identified from patents. Hilton Worldwide's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Treating keloids using hif-1 inhibiting compounds

Source: United States Patent and Trademark Office (USPTO). Credit: Hilton Worldwide Holdings Inc

A recently granted patent (Publication Number: US11672797B2) discloses a method for treating keloids in human subjects. The method involves administering a therapeutically effective amount of a hypoxia-inducible factor-1 (HIF-1)-inhibiting compound, which has been determined through an assay to induce cell death in keloids. The patent claims that the HIF-1-inhibiting compound can be selected from a group of compounds including N,N'-(Dithiodi-2,1-ethanediyl)bis[2,5-dichlorobenzenesulfonamide (KC7F2), 2-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one (IDF-11774), (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide dihydrochloride (PX-478), and their pharmaceutically acceptable salts.

The method can also involve the administration of a glycolysis inhibitor, specifically 2-deoxyglucose (2-DG), in addition to the HIF-1-inhibiting compound. The patent further claims a method for inducing cell death in keloids by directly contacting the keloids with a HIF-1-inhibiting compound in an effective amount determined through an assay. Similar to the previous method, this method can also involve the use of a glycolysis inhibitor, such as 2-DG, to enhance the induction of cell death in keloids.

The patent emphasizes that the HIF-1-inhibiting compound blocks the ability of HIF-1a to form a holoprotein, which is believed to play a role in the development and progression of keloids. By inhibiting HIF-1a, the compound aims to induce cell death in keloids, potentially leading to the reduction or elimination of keloid tissue.

Overall, this granted patent presents methods for treating keloids by administering HIF-1-inhibiting compounds and potentially combining them with glycolysis inhibitors. The patent claims that these methods can effectively induce cell death in keloids, offering a potential therapeutic approach for the treatment of keloid scars in human subjects.

To know more about GlobalData’s detailed insights on Hilton Worldwide, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.